Skip to content

Electromechanical Profiling of the Long-QT Syndrome (LQTS)

Electromechanical Profiling of Arrhythmogenic Substrates and Triggers in the Long-QT Syndrome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04074122
Acronym
EMLoQ
Enrollment
150
Registered
2019-08-29
Start date
2020-01-01
Completion date
2022-01-01
Last updated
2019-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long QT Syndrome, Sudden Cardiac Death, Ventricular Tachycardia

Keywords

Electromechanical Mapping, Risk Stratification

Brief summary

High-resolution, non-invasive electromechanical mapping in genotyped long-QT syndrome patients and healthy controls at baseline and during smart provocation.

Detailed description

Using simultaneous ECG-imaging, speckle-tracking analysis and tissue-phase mapping with MRI we will assess electromechanical dispersion at rest. Regional electromechanical elasticity will be investigated during adenosine and epinephrine, isoprenaline infusions and is postulated to increase sudden cardiac death risk prediction in the individual patient.

Interventions

DIAGNOSTIC_TESTAdenosine and epinephrine, isoprenaline provocation

High-resolution electromechanical mapping at baseline and after provocative measures.

Sponsors

University of Freiburg
CollaboratorOTHER
University of Bern
CollaboratorOTHER
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

LQTS group (Group 1): * Diagnosis of LQTS according to the ESC guidelines. * Genetic testing either already performed or consent to genetic testing (at least 5 major LQTS-related genes tested: KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2). Control group (Group 2): \> Control subjects with structurally normal hearts.

Exclusion criteria

* Pregnancy, nursing or planning to become pregnant. * Known allergy or strong reaction to skin electrodes or contrast agent. * Inability to give informed consent. * Presence of metal objects in or attached to the body. * Dialysis. * Cardiomyopathy. * Second-degree heart block or higher degrees of block. * Sick sinus syndrome. * Asthma. * Chronic obstructive pulmonary disease. * Left-main coronary artery disease. * Unstable coronary artery disease.

Design outcomes

Primary

MeasureTime frameDescription
Differences in regional electromechanical dispersion between LQTS patients and controlsAt day of investigationElectromechanical dispersion in milliseconds
Differences in regional electromechanical dispersion between symptomatic and asymptomatic LQTS patientsAt day of investigationElectromechanical dispersion in milliseconds

Secondary

MeasureTime frameDescription
Correlation of electromechanical dispersion between LQTS type 1, 2, and 3.At day of investigationElectromechanical dispersion in milliseconds
Relation between global electromechanical window vs regional electromechanical dispersion in LQTSAt day of investigationElectromechanical dispersion in milliseconds
Correlation between mechanical dispersion using TPM-MRI and cine-MRIAt day of investigationTime-to-diastolic peak in milliseconds
Correlation between mechanical dispersion using TPM-MRI and speckle-tracking echocardiographyAt day of investigationTime-to-peak in milliseconds

Contacts

Primary ContactRachel ter Bekke, MD, PhD
rachel.ter.bekke@mumc.nl+31433877095
Backup ContactPaul Volders, MD, PhD
p.volders@maastrichtuniversity.nl+31433877093

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026